Skip to main content
. 2023 Oct 7;31(12):3531–3544. doi: 10.1016/j.ymthe.2023.10.004

Figure 5.

Figure 5

PBMC cytotoxicity against MSCs (Alofisel/darvadstrocel) and increment of PGE2 are associated with clinical response to MSC therapy

MSC (Alofisel/darvadstrocel) apoptosis (A) and PGE2 levels (D) were compared in the MSC arm between patients who never responded to treatment and patients who responded either 6, 12, or 24 weeks after treatment. (B and E) ROC curve analysis for ApoMSC and PGE biomarkers. (B) ApoMSC yielded an AUC of 0.8 (95% CI: 0.61–0.99, p = 0.01) with 78% sensitivity and 75% specificity selecting a cutoff value of 9.79. (E) PGE2 yielded an AUC of 0.84 (95% CI: 0.68–1, p = 0.007). A PGE2 value > 2,008 pg/mL detected clinical response with 81% sensitivity and 75% specificity. (C and F) MSC apoptosis (C) and PGE2 (F) were assessed in patients who maintained remission and patients who relapsed. Unpaired t test or Mann-Whitney test was used to analyze mean differences between the groups (∗p values <0.05, ∗∗p values <0.01, ns, not significant).